Siemens Healthineers: Clinical Excellence Meets a Market That Isn’t Listening

Siemens Healthineers shares trade near 52-week low despite strong clinical integration, AI innovations, and strategic partnerships; diagnostics segment remains a drag.

The numbers tell a grim story—Siemens Healthineers shares are trading at €34.28, barely four percent above their 52-week low of €32.84. The stock has lost nearly 23% since the start of the year and sits more than 17% below its 200-day moving average of €41.37. The 38-day line was breached on Thursday, a classic sell signal, while the relative strength index at 44.7 points to neutral-to-weak momentum but not yet oversold territory. Yet beneath that bearish surface, the underlying business is putting together an increasingly compelling case.

The core that keeps delivering

The strongest argument for Siemens Healthineers lies not in financial engineering but in clinical relevance. The company recently equipped the new University Heart and Vascular Center at Hamburg’s University Medical Center (UKE) with imaging technology for interventional suites, hybrid operating rooms, and a cardiovascular imaging center. That kind of deep integration into hospital workflows creates switching costs and opens doors for follow-on innovations—far more valuable than a one-off equipment sale.

A planned strategic research partnership with UKE will target cardiology, radiology, and data-driven medicine. These are not short-term catalysts, but they underscore how Siemens Healthineers positions itself at the intersection of medical workflows, data, and imaging. The company sells more than machines; it sells embedded clinical solutions.

AI as a scalpel, not a sledgehammer

Siemens Healthineers has been careful not to pitch AI as a vague promise. The CE marking for AI-powered contouring in the Varian Eclipse radiation therapy environment is a case in point: it reduces manual work and variability in treatment planning while keeping clinicians in control. Similarly, the collaboration with Cercare Medical brings cone-beam CT perfusion imaging directly into the angiography suite, cutting down on patient transfers during stroke care. This is AI deployed at the bottlenecks of acute medicine—credible, tangible, and defensible.

The arrival of Martin Stumpe as chief technology officer in June reinforces that digital push. Stumpe, whose previous stops include Google, NASA, and rival Danaher, has been tasked with building out software capabilities to offset rising costs and regulatory pressure. The company is investing heavily in artificial intelligence and “patient twinning”—digital replicas used for more precise diagnoses. The ambition is clear; now it must produce results.

Diagnostics remains the missing piece

The Diagnostics segment continues to act as a drag. Management blamed structural changes in the Chinese diagnostics market and higher inflation expectations for an adjusted outlook. The division is difficult terrain, and it explains why the stock has not yet broken free from its downtrend. But the company is increasingly drawing a line between its “synergistic core” of Imaging and Precision Therapy and the problem child that is Diagnostics. Options for Diagnostics are being prepared, and the message from management is that they are thinking about it separately.

That message was reinforced at the J.P. Morgan European Healthcare Forum in London, where executives courted institutional investors. These appearances are meant to rebuild confidence, but the market appears to be waiting for more concrete action.

The structural overhang that won’t go away

Siemens AG is preparing to significantly reduce its stake in Siemens Healthineers, with the annual general meeting expected to formalize the move in February 2027. The plan involves a direct distribution of shares to Siemens shareholders, effectively spinning off the medtech division. Until that process is completed, a portion of the market will likely hold back—waiting to see how the shareholder base, strategic independence, and market perception actually shift.

This is more a valuation problem than a business model problem. If the disentanglement succeeds, Siemens Healthineers could be viewed more clearly as a standalone medtech core value. If it drags on, the operating strength remains intact—but the market will wait longer for the clearing moment.

China: playing the long game

In parallel, Siemens Healthineers received approval in China for its first locally produced photon-counting CT scanner, the NAEOTOM Alpha.Pro. With geopolitical tensions and strict local procurement rules, a local value chain is now effectively a prerequisite for market access. The move shows that the company is investing to protect its position in one of the world’s largest healthcare markets, even as Diagnostics faces headwinds there.

Waiting for clarity—but the foundation is solid

Siemens Healthineers is in a frustrating moment: the operational engines in Imaging and Precision Therapy are running well, the clinical partnerships are deepening, and the digital strategy has a credible leader. Yet the stock is stuck near lows because of Diagnostics and the ownership structure. The next quarterly report will be a critical test—and so will the ability of recent investor roadshows to unlock new institutional capital.

The bull case rests on the idea that the market is underestimating the core business while fixating on temporary drags. The bear case warns that Diagnostics and the spin-off uncertainty could weigh for longer. For now, the operating arguments outweigh the structural ones—provided management delivers the clarity on Diagnostics and the spin-off that investors are still waiting for.